Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 506
- Registration Number
- NCT03093324
- Locations
- 🇵🇱
Alkermes Investigational Site, Szczecin, Poland
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Other: Vitamin K CreamOther: Placebo Cream
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 23
- Registration Number
- NCT03091569
- Locations
- 🇮🇹
Research Site, Napoli, Italy
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
- Conditions
- Behavioral Variant Frontotemporal DementiaFrontotemporal Dementia
- Interventions
- Other: Assessments
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT03088956
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Long-Term Evaluation of BIIB067 (Tofersen)
- Conditions
- ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 139
- Registration Number
- NCT03070119
- Locations
- 🇬🇧
Research Site, Sheffield, South Yorkshire, United Kingdom
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Biogen
- Registration Number
- NCT03070132
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 490
- Registration Number
- NCT03068468
- Locations
- 🇬🇧
Research Site, London, United Kingdom
🇺🇸Research Name, Chicago, Illinois, United States
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
- Conditions
- Alzheimer's DiseaseHealthy Volunteer
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 46
- Registration Number
- NCT03056729
- Locations
- 🇺🇸
St Louis Clinical Trial, Saint Louis, Missouri, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 102
- Registration Number
- NCT03000530
- Locations
- 🇺🇸
Sage Investigational Site, Charlottesville, Virginia, United States
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 29
- Registration Number
- NCT03000569
- Locations
- 🇺🇸
Sage Investigational Site, Orem, Utah, United States
MS PATHS Normative Sub-Study
- Conditions
- Healthy Volunteer
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 246
- Registration Number
- NCT02996084
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇪🇸Multiple Sclerosis Centre of Catalonia (Cemcat) Vall d'Hebron Hospital, Barcelona, Spain